
Supplementary Figure 5

Principle Component Analysis in different subtypes compared to match HV.

a-d. Serine Threonine kinase (STK)


а

HR-positive HER2 negative pts Vs HVs



b

HR-positive HER2 positive pts Vs HVs





С

Triple negative pts Vs HVs



HR-negative HER2 positive pts Vs HVs






e-h. Phosphotyrosine kinase (PTK)


е

HR-positive HER2 negative patients Vs HVs




g






f HR-positive HER2 positive patients Vs HVs



h

HR-negative HER2 positive patients Vs



Principle Component Analysis in different subtypes compared to match HV. a-d: Principal Component Analysis (PCA) of the different subtypes of breast cancer compared to HVs for the STK family of kinases. a. HR-positive HER2 negative breast cancer (represented by ER pos) and HVs (represented by C Healthy); b: patients with HRpositive HER2 positive breast cancer (represented by ER pos HER2 pos) and HVs (represented by C Healthy); c: patients with HR-negative HER2 positive breast cancer (represented by ER neg HER2 pos) and HVs (represented by C Healthy); d: patients with

Triple negative breast cancer (represented by Triple neg) and HVs (represented by C Healthy).

e-h Principal Component Analysis (PCA) of the different subtypes of breast cancer compared to HVs for the PTK family of kinases. e: patients with HR-positive HER2 negative breast cancer (represented by ER pos) and HVs (represented by C Healthy); f: patients with HR-positive HER2 positive breast cancer (represented by ER pos HER2 pos) and HVs (represented by C Healthy); g: patients with HR-negative HER2 positive breast cancer (represented by ER neg HER2 pos) and HVs (represented by C Healthy); h: patients with Triple negative breast cancer (represented by Triple neg) and HVs (represented by C Healthy).